Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX60 Plus Serplulimab in Advanced Solid Tumors
NCT05483530Phase 1Unknown
- Sponsor
- Henlius
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLX60 in solid tumor, sponsored by Henlius. Primary endpoints: Adverse Event at 2 years, Incidence of Dose Limiting Toxicity at 3 weeks and 2 more. Status: unknown.
02
Drugs
HLX60
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05483530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483530.